CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 34 enrolled
Drug / intervention
AcrySof ReSTOR Aspheric IOLdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00818116
NCT00818116Phase 4Completed
CompareCT.gov

Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric Intraocular Lens (IOL): Postmarket Evaluation

Alcon Research·interventional·Posted Jan 7, 2009·Updated Jul 30, 2010

In Brief

A Phase 4 clinical trial evaluating AcrySof ReSTOR Aspheric IOL for Cataracts. Completed, enrolled 34 participants across 1 site.

Detailed Summary

The objective of this study is to evaluate postoperative visual function in patients implanted bilaterally with the ReSTOR Aspheric Intraocular Lens (IOL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataracts
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 7, 2009
Enrollment StartDec 1, 2008
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.5 years ago

Interventions

AcrySof ReSTOR Aspheric IOLdevice

Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL) for the replacement of cataract in the natural lens of the eye.